1. |
汪晓东, 吕炘沂, 黄明君, 等. 数据库建设第二部分: 结直肠癌住院流程管理的标签与结构化. 中国普外基础与临床杂志, 2019, 26(7): 852-855.
|
2. |
汪晓东, 李立. 数据库建设第一部分: 个人数据的标签与结构化. 中国普外基础与临床杂志, 2019, 26(3): 335-342.
|
3. |
汪晓东, 刘健博, 安丽珉, 等. 数据库建设第四部分: 结直肠癌的术前专科检查与评估的标签与结构化, 2019, 26(11): 1337-1341.
|
4. |
Dijkstra EA, Hospers GAP, Kranenbarg EM, et al. Quality of life and late toxicity after short-course radiotherapy followed by chemotherapy or chemoradiotherapy for locally advanced rectal cancer—The RAPIDO trial. Radiother Oncol, 2022, 171: 69-76.
|
5. |
Yang J, Wang W, Luo Y, et al. Effect of pathological complete response after neoadjuvant chemoradiotherapy on postoperative complications of rectal cancer: a systematic review and meta-analysis. Tech Coloproctol, 2022, 26(3): 163-174.
|
6. |
Lin W, Li C, Clement EA, et al. Surgical outcomes in total neoadjuvant therapy for rectal cancer versus standard long-course chemoradiation: a systematic review and meta-analysis of randomized controlled trials. Ann Surg, 2024, 279(4): 620-630.
|
7. |
Gollins S, Sebag-Montefiore D. Neoadjuvant treatment strategies for locally advanced rectal cancer. Clin Oncol (R Coll Radiol), 2016, 28(2): 146-151.
|
8. |
国家卫生健康委员会医政司, 中华医学会肿瘤学分会. 中国结直肠癌诊疗规范(2023版). 协和医学杂志, 2023, 14(4): 706-733.
|
9. |
Engstrom PF, Arnoletti JP, Benson AB, et al. NCCN clinical practice guidelines in oncology: rectal cancer. J Natl Compr Canc Netw, 2009, 7(8): 838-881.
|
10. |
Gerard JP, Barbet N, Schiappa R, et al. Neoadjuvant chemoradiotherapy with radiation dose escalation with contact X-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2-cT3 rectal adenocarcinoma (OPERA): a phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol, 2023, 8(4): 356-367.
|
11. |
Tan S, Ou Y, Huang S, et al. Surgical, oncological, and functional outcomes of local and radical resection after neoadjuvant chemotherapy or chemoradiotherapy for early- and mid-stage rectal cancer: a systematic review and meta-analysis. Int J Colorectal Dis, 2023, 38(1): 132. doi: 10.1007/s00384-023-04433-6.
|
12. |
汪晓东, 刘健博, 安丽珉, 等. 数据库研究第四部分: 结直肠癌的术前专科检查与评估. 中国普外基础与临床杂志, 2019, 26(10): 1230-1238.
|
13. |
汪晓东, 由屹先, 余其澳, 等. 数据库建设第九部分: 结直肠癌新辅助治疗的标签与结构化. 中国普外基础与临床杂志, 2021, 28(6): 799-804.
|
14. |
陈功勤, 张洋, 郭慧, 等. 不同新辅助治疗方案对直肠癌患者TRG、手术并发症及LARS的影响. 肿瘤防治研究, 2021, 48(12): 1108-1112.
|
15. |
李立, 汪晓东. 以价值医疗为导向的结直肠癌标准数据集. 四川科学技术出版社, 2023.
|
16. |
Bahadoer RR, Dijkstra EA, van Etten B, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol, 2021, 22(1): 29-42.
|
17. |
Påhlman L. Neoadjuvant and adjuvant radio- and radio-chemotherapy of rectal carcinomas. Int J Colorectal Dis, 2000, 15(1): 1-8.
|
18. |
汪泓, 罗文广, 张红雁, 等. 直肠癌新辅助放化疗后病理完全缓解的临床预测因素分析. 安徽医学, 2024, 45(9): 1100-1105.
|
19. |
刘健博, 吕炘沂, 邹雨恒, 等. 多周期新辅助化疗联合阿帕替尼对进展期直肠癌的疗效评价: 基于DACCA数据库的辅助研究. 中国普外基础与临床杂志, 2019, 26(6): 728-734.
|
20. |
汪晓东, 邱萌, 李亚伦, 等. 多学科协作诊治模式下结直肠癌不同周期新辅助化疗联合手术的方案研究. 中国普外基础与临床杂志, 2008, 15(3): 210-214, 217.
|
21. |
Deng Y, Chi P, Lan P, et al. Modified FOLFOX6 with or without radiation versus fluorouracil and leucovorin with radiation in neoadjuvant treatment of locally advanced rectal cancer: Initial results of the Chinese FOWARC multicenter, open-label, randomized three-arm phase Ⅲ trial. J Clin Oncol, 2016, 34(27): 3300-3307.Deng Y, Chi P, Lan P, et al. Modified FOLFOX6 with or without radiation versus fluorouracil and leucovorin with radiation in neoadjuvant treatment of locally advanced rectal cancer: Initial results of the Chinese FOWARC multicenter, open-label, randomized three-arm phase Ⅲ trial. J Clin Oncol, 2016, 34(27): 3300-3307.
|
22. |
郭旭飞. 术前短程放疗联合新辅助化疗治疗中低位局部进展期直肠癌效果及安全性分析. 中国医学物理学杂志, 2024, 41(12): 1481-1485.
|
23. |
胡欲飞. 新辅助化疗Folfoxiri方案在中低位进展期直肠癌治疗的安全性和有效性分析. 十堰: 湖北医药学院, 2024.
|
24. |
Cercek A, Roxburgh CSD, Strombom P, et al. Adoption of total neoadjuvant therapy for locally advanced rectal cancer. JAMA Oncol, 2018, 4(6): e180071. doi: 10.1001/jamaoncol.2018.0071.
|
25. |
Garcia-Aguilar J, Patil S, Gollub MJ, et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol, 2022, 40(23): 2546-2556.
|
26. |
万觉锋, 章真. 直肠癌术前放疗进展. 中华结直肠疾病电子杂志, 2016, 5(2): 127-132.
|
27. |
Helbling D, Bodoky G, Gautschi O, et al. Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase Ⅱ trial SAKK 41/07. Ann Oncol, 2013, 24(3): 718-725.
|
28. |
Pinto C, Di Fabio F, Maiello E, et al. Phase Ⅱ study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study). Ann Oncol, 2011, 22(11): 2424-2430.
|
29. |
Bertolini F, Chiara S, Bengala C, et al. Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase Ⅱ study in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys, 2009, 73(2): 466-472.
|
30. |
Kripp M, Horisberger K, Mai S, et al. Does the addition of cetuximab to radiochemotherapy improve outcome of patients with locally advanced rectal cancer? Long-term results from phase Ⅱ trials. Gastroenterol Res Pract, 2015, 2015: 273489. doi: 10.1155/2015/273489.
|
31. |
刘勇, 汪晓东, 由屹先, 等. 数据库研究第九部分: 结直肠癌的新辅助治疗. 中国普外基础与临床杂志, 2021, 28(5): 657-663.
|
32. |
中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)结直肠癌诊疗指南. 北京: 人民卫生出版社, 2023.
|
33. |
Mbanu P, Saunders MP, Mistry H, et al. Clinical and radiomics prediction of complete response in rectal cancer pre-chemoradiotherapy. Phys Imaging Radiat Oncol, 2022, 23: 48-53.Mbanu P, Saunders MP, Mistry H, et al. Clinical and radiomics prediction of complete response in rectal cancer pre-chemoradiotherapy. Phys Imaging Radiat Oncol, 2022, 23: 48-53.
|
34. |
Gérard JP, Chamorey E, Gourgou-Bourgade S, et al. Clinical complete response (cCR) after neoadjuvant chemoradiotherapy and conservative treatment in rectal cancer. Findings from the ACCORD 12/PRODIGE 2 randomized trial. Radiother Oncol, 2015, 115(2): 246-252.Gérard JP, Chamorey E, Gourgou-Bourgade S, et al. Clinical complete response (cCR) after neoadjuvant chemoradiotherapy and conservative treatment in rectal cancer. Findings from the ACCORD 12/PRODIGE 2 randomized trial. Radiother Oncol, 2015, 115(2): 246-252.
|
35. |
卢琳, 赵清叶, 宋婷婷, 等. 老年局部进展期中低位直肠癌新辅助放化疗效果的影响因素. 中国老年学杂志, 2019, 39(19): 4726-4728.
|
36. |
Maas M, Beets-Tan RG, Lambregts DM, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol, 2011, 29(35): 4633-4640.
|
37. |
杨庆, 张涛. 直肠癌新辅助治疗后临床完全缓解的评估. 现代肿瘤医学, 2016, 24(17): 2815-2819.
|
38. |
Kong JC, Guerra GR, Warrier SK, et al. Prognostic value of tumour regression grade in locally advanced rectal cancer: a systematic review and meta-analysis. Colorectal Dis, 2018, 20(7): 574-585.
|
39. |
Lu X, Qi R, Xu Y, et al. Tumor regression grade in locally advanced rectal cancer after neoadjuvant chemoradiotherapy: influencing factors and prognostic significance. Int J Clin Exp Pathol, 2023, 16(6): 124-132.
|
40. |
何蕾. 直肠癌新辅助放化疗后淋巴结与肿瘤消退分级相关性研究. 电子科技大学, 2023.
|
41. |
Boldrini L, Charles-Davies D, Romano A, et al. Response prediction for neoadjuvant treatment in locally advanced rectal cancer patients-improvement in decision-making: A systematic review. Eur J Surg Oncol, 2024 Nov 15: 109463. doi: 10.1016/j.ejso.2024.109463.
|
42. |
胡义銧, 刘碧瑶, 张雯迪, 等. 基于CT影像组学的局部进展期直肠癌新辅助放化疗效果的预测模型研究. 中国普外基础与临床杂志, 2025, 32(2): 205-212.
|
43. |
Beddy D, Hyland JM, Winter DC, et al. A simplified tumor regression grade correlates with survival in locally advanced rectal carcinoma treated with neoadjuvant chemoradiotherapy. Ann Surg Oncol, 2008, 15(12): 3471-3477.Beddy D, Hyland JM, Winter DC, et al. A simplified tumor regression grade correlates with survival in locally advanced rectal carcinoma treated with neoadjuvant chemoradiotherapy. Ann Surg Oncol, 2008, 15(12): 3471-3477.
|
44. |
薛立杰. 局部进展期直肠癌新辅助放化疗后肿瘤消退分级的影响因素及预后分析. 福州: 福建医科大学, 2017.
|
45. |
Xu L, Cai S, Xiao T, et al. Prognostic significance of tumour regression grade after neoadjuvant chemoradiotherapy for a cohort of patients with locally advanced rectal cancer: an 8-year retrospective single-institutional study. Colorectal Dis, 2017, 19(7): O263-O271. doi: 10.1111/codi.13757.
|
46. |
Park YJ, Oh BR, Lim SW, et al. Clinical significance of tumor regression grade in rectal cancer with preoperative chemoradiotherapy. J Korean Soc Coloproctol, 2010, 26(4): 279-286.Park YJ, Oh BR, Lim SW, et al. Clinical significance of tumor regression grade in rectal cancer with preoperative chemoradiotherapy. J Korean Soc Coloproctol, 2010, 26(4): 279-286.
|
47. |
Bozzetti F, Andreola S, Bertario L. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis, 1998, 13(1): 54-55.Bozzetti F, Andreola S, Bertario L. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis, 1998, 13(1): 54-55.
|
48. |
吴桂儀, 贺子妍, 唐盈, 等. 结直肠癌患者居住地与新辅助依从性、方案决策和疗效的关系: 基于DACCA的真实世界数据研究. 中国普外基础与临床杂志, 2023, 30(8): 911-918.
|
49. |
唐盈, 苏语, 聂皓苒, 等. 结直肠癌患者的文化程度与新辅助方案决策和疗效的关系: 基于DACCA的真实世界数据研究. 中国普外基础与临床杂志, 2023, 30(10): 1200-1204.
|